Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. MAIA Biotechnology is developing a Telomerase-Mediated Approach to Fighting Cancer. Telomerase is either absent or shows low activity in normal cells. THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres. Once incorporated, it compromises telomere …
AI, Genome Sequencing and New Sensors Creates Pre-Cancer Management
It’s a question that everybody’s asking, since everyone knows someone who has been diagnosed or is currently dealing with some form of cancer: just how close are we to curing the disease? We’re at a point where a cancer diagnosis is scary, but manageable in many cases. After getting a breast cancer diagnosis, for example, …
A new cancer drugs work by targeting tumors by their genetic make-up instead of where originate in the body. On November 26, 2018, the Food and Drug Administration granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) …
A combination treatment of intensive chemotherapy and radiation therapy, as well as the blood pressure drug losartan enables many previously inoperable pancreatic cancer tumors to be removed. The work was done at Massachusetts General Hospital and will expand to more institutions in an expanded study. Using the combo therapy allowed 34 of the 49 participants …
Mayo Clinic Dr. Truty and his colleagues start treating pancreatic cancer with new chemotherapy drugs before surgery, rather than afterward and are able to increase survival rates by five times.
TAE Life Sciences, division of TAE Technologies, will use low energy neutrons to destroy cancer tumors without damaging healthy tissue. They are using nuclear science know-how that they have built up from their continuing pursuit of commercial nuclear fusion to develop a more effective million cancer radiation treatment device. TAE raised $40 million to build …
Advancing toward a whole new hybrid field of protein-DNA nanotechnology with capabilities beyond DNA and Protein nanotechnology alone.
Jim Mellon is a billionaire investor in antiaging companies. Jim has made several investments in antiaging companies and as one of the leading investors in the field gets pitched almost all of the antiaging companies. Jim thus has a unique perspective on what the latest developments are with anti-aging technology. Jim predicts that average life …
The entire genome of the white shark has now been decoded in detail. The white shark genome was also compared to gthe genomes of other vertebrates including the giant whale shark and humans. The white shark has a genome that is one and half time larger than the human genome. Very large-bodied animals do not …
Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say the AEBi anti-cancer treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order. They are using peptides. MuTaTo is using a combination of several cancer-targeting peptides for each …
